兴奋剂
内科学
双盲
医学
随机对照试验
药理学
受体
替代医学
病理
安慰剂
作者
Samer Gawrieh,Mazen Noureddin,Nicole Loo,Rizwana Mohseni,Vivek Awasty,Kenneth Cusi,Kris V. Kowdley,Michelle Lai,Eugene R. Schiff,Dhruvanshu Parmar,Pankaj Patel,Naga Chalasani
出处
期刊:Hepatology
[Lippincott Williams & Wilkins]
日期:2021-04-03
卷期号:74 (4): 1809-1824
被引量:335
摘要
Saroglitazar 4 mg significantly improved ALT, LFC, insulin resistance, and atherogenic dyslipidemia in participants with NAFLD/NASH. (ClinicalTrials.gov identifier: NCT03061721.).
科研通智能强力驱动
Strongly Powered by AbleSci AI